Immetas Therapeutics, Inc.

Immetas Therapeutics, Inc. is focused on discovering and developing innovative therapeutics aimed at the innate immune system to combat age-related cancers and inflammatory diseases, addressing critical healthcare challenges. Immetas Therapeutics, Inc. specializes in the discovery and development of therapeutics targeting the innate immune system.

Founded in 2018 in the US by J Wang, the company has made one significant deal, raising USD 11 mn in Series A funding from Morningside Venture Capital on September 23, 2020. J Wang is also the CEO of the company, bringing relevant experience to its leadership. Immetas specializes in innovative therapeutics that target the innate immune system to manage age-related cancers and inflammatory diseases. The company’s core offerings focus on modulating chronic low-grade inflammation, pivotal in the aging process and related diseases.

Immetas develops a product pipeline addressing unmet medical needs in oncology and autoimmune therapy markets, marketed primarily in North America and Europe, targeting research institutions and clinical settings where demand for effective treatments is increasing. Immetas generates revenue through product sales and strategic partnerships in the healthcare sector. The company engages in direct-to-consumer transactions and B2B agreements with hospitals and clinics using its therapeutics for patient care. Revenue streams come from flagship products priced based on therapeutic applications, ensuring accessibility while maintaining robust revenue.

Collaborative efforts include joint ventures or licensing agreements, expanding market reach. Immetas Therapeutics, Inc. plans to utilize the recent USD 11 mn raised in Series A funding to support the development of upcoming innovative products targeting chronic inflammation-related conditions. The company aims to expand its presence in both North America and Europe, specifically increasing its market penetration in emerging healthcare markets by 2025.

This funding will be pivotal in advancing their therapeutic pipeline and enhancing market access for future offerings.